Abstract
In an open trial, patients with ICD-10 diagnosis of acute functional psychoses were administered injection Zuclopenthixol acetate (Acuphase) in the initial phase. Patients were rated with CGI, BPRS -24 item and UKU side effect rating scale at baseJine, 24 hours and 72 hours. Of the 120 patients recruited, 119 finished this part of the trial. The most common side effect was sedation, which was preferable as most of the patients were in the acute state. The issues concerning less dosing efficacy and the rapid onset of antipsychotic activity are discussed.
Patients who had been administered zuclopenthixol acetate in the acute phase were maintained with injection zuclopenthixol decanoate (depot) starting at 72 hours over the baseline. Patients were assessed at 72 hours, one week, 2 weeks, 3 vseeks, 4 weeks and 8 weeks using the same instruments. The issues concerning the dosage and therapeutic efficacy are discussed.
Keywords: Zuclopenthixol acetate, acute psychoses, zuclopenthixol decanoate, depot
Full Text
The Full Text of this article is available as a PDF (289.0 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Ahlfors U. G., Dencker S. J., Gravem A., Remvig J. Clopenthixol decanoate and perphenazine enanthate in schizophrenic patients. A double-blind Nordic multicentre trial. Acta Psychiatr Scand Suppl. 1980;279:77–91. doi: 10.1111/j.1600-0447.1980.tb07085.x. [DOI] [PubMed] [Google Scholar]
- Amdisen A., Aaes-Jørgensen T., Thomsen N. J., Madsen V. T., Nielsen M. S. Serum concentrations and clinical effect of zuclopenthixol in acutely disturbed, psychotic patients treated with zuclopenthixol acetate in Viscoleo. Psychopharmacology (Berl) 1986;90(3):412–416. doi: 10.1007/BF00179201. [DOI] [PubMed] [Google Scholar]
- Amdisen A., Nielsen M. S., Dencker S. J., Fensbo C., Ahlfors U. G., Gravem A., Baastrup P. C., Bjerkenstedt L., Gunby B., Wiesel F. A. Zuclopenthixol acetate in Viscoleo--a new drug formulation. An open Nordic multicentre study of zuclopenthixol acetate in Viscoleo in patients with acute psychoses including mania and exacerbation of chronic psychoses. Acta Psychiatr Scand. 1987 Jan;75(1):99–107. doi: 10.1111/j.1600-0447.1987.tb02759.x. [DOI] [PubMed] [Google Scholar]
- Dencker S. J., Lepp M., Malm U. Clopenthixol and flupenthixol depot preparations in outpatient schizophrenics. I. A one year double-blind study of clopenthixol decanoate and flupenthixol palmitate. Acta Psychiatr Scand Suppl. 1980;279:10–28. doi: 10.1111/j.1600-0447.1980.tb07080.x. [DOI] [PubMed] [Google Scholar]
- Matar A. M., Abdel-Mawgoud M., Skov S. Zuclopenthixol: a new generation of antipsychotic drugs. An open clinical trial. J Clin Psychopharmacol. 1990 Aug;10(4):283–286. [PubMed] [Google Scholar]
- Schlosberg A., Barr F. Zuclopenthixol acetate in viscoleo in acutely disturbed psychotic patients. Isr J Psychiatry Relat Sci. 1991;28(2):60–63. [PubMed] [Google Scholar]
- Wistedt B., Koskinen T., Thelander S., Nerdrum T., Pedersen V., Mølbjerg C. Zuclopenthixol decanoate and haloperidol decanoate in chronic schizophrenia: a double-blind multicentre study. Acta Psychiatr Scand. 1991 Jul;84(1):14–21. doi: 10.1111/j.1600-0447.1991.tb01414.x. [DOI] [PubMed] [Google Scholar]